Schaid Daniel J, McDonnell Shannon K, Zarfas Katherine E, Cunningham Julie M, Hebbring Scott, Thibodeau Stephen N, Eeles Rosalind A, Easton Douglas F, Foulkes William D, Simard Jacques, Giles Graham G, Hopper John L, Mahle Lovise, Moller Pal, Badzioch Michael, Bishop D Timothy, Evans Chris, Edwards Steve, Meitz Julia, Bullock Sarah, Hope Questa, Guy Michelle, Hsieh Chih-lin, Halpern Jerry, Balise Raymond R, Oakley-Girvan Ingrid, Whittemore Alice S, Xu Jianfeng, Dimitrov Latchezar, Chang Bao-Li, Adams Tamara S, Turner Aubrey R, Meyers Deborah A, Friedrichsen Danielle M, Deutsch Kerry, Kolb Suzanne, Janer Marta, Hood Leroy, Ostrander Elaine A, Stanford Janet L, Ewing Charles M, Gielzak Marta, Isaacs Sarah D, Walsh Patrick C, Wiley Kathleen E, Isaacs William B, Lange Ethan M, Ho Lindsey A, Beebe-Dimmer Jennifer L, Wood David P, Cooney Kathleen A, Seminara Daniela, Ikonen Tarja, Baffoe-Bonnie Agnes, Fredriksson Henna, Matikainen Mika P, Tammela Teuvo L J, Bailey-Wilson Joan, Schleutker Johanna, Maier Christiane, Herkommer Kathleen, Hoegel Josef J, Vogel Walther, Paiss Thomas, Wiklund Fredrik, Emanuelsson Monica, Stenman Elisabeth, Jonsson Björn-Anders, Grönberg Henrik, Camp Nicola J, Farnham James, Cannon-Albright Lisa A, Catalona William J, Suarez Brian K, Roehl Kimberly A
Harwick 7, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Hum Genet. 2006 Nov;120(4):471-85. doi: 10.1007/s00439-006-0219-9. Epub 2006 Aug 25.
While it is widely appreciated that prostate cancers vary substantially in their propensity to progress to a life-threatening stage, the molecular events responsible for this progression have not been identified. Understanding these molecular mechanisms could provide important prognostic information relevant to more effective clinical management of this heterogeneous cancer. Hence, through genetic linkage analyses, we examined the hypothesis that the tendency to develop aggressive prostate cancer may have an important genetic component. Starting with 1,233 familial prostate cancer families with genome scan data available from the International Consortium for Prostate Cancer Genetics, we selected those that had at least three members with the phenotype of clinically aggressive prostate cancer, as defined by either high tumor grade and/or stage, resulting in 166 pedigrees (13%). Genome-wide linkage data were then pooled to perform a combined linkage analysis for these families. Linkage signals reaching a suggestive level of significance were found on chromosomes 6p22.3 (LOD = 3.0), 11q14.1-14.3 (LOD = 2.4), and 20p11.21-q11.21 (LOD = 2.5). For chromosome 11, stronger evidence of linkage (LOD = 3.3) was observed among pedigrees with an average at diagnosis of 65 years or younger. Other chromosomes that showed evidence for heterogeneity in linkage across strata were chromosome 7, with the strongest linkage signal among pedigrees without male-to-male disease transmission (7q21.11, LOD = 4.1), and chromosome 21, with the strongest linkage signal among pedigrees that had African American ancestry (21q22.13-22.3; LOD = 3.2). Our findings suggest several regions that may contain genes which, when mutated, predispose men to develop a more aggressive prostate cancer phenotype. This provides a basis for attempts to identify these genes, with potential clinical utility for men with aggressive prostate cancer and their relatives.
虽然人们普遍认识到前列腺癌发展到危及生命阶段的倾向差异很大,但导致这种进展的分子事件尚未明确。了解这些分子机制可为这种异质性癌症的更有效临床管理提供重要的预后信息。因此,通过基因连锁分析,我们检验了以下假设:侵袭性前列腺癌的发生倾向可能有重要的遗传因素。我们从国际前列腺癌遗传学联盟获得的1233个有基因组扫描数据的家族性前列腺癌家族开始,选择那些至少有三名成员具有临床侵袭性前列腺癌表型的家族,临床侵袭性前列腺癌的表型定义为高肿瘤分级和/或分期,最终得到166个家系(13%)。然后汇总全基因组连锁数据,对这些家族进行联合连锁分析。在6号染色体p22.3区域(LOD = 3.0)、11号染色体q14.1 - 14.3区域(LOD = 2.4)和20号染色体p11.21 - q11.21区域(LOD = 2.5)发现了达到提示性显著水平的连锁信号。对于11号染色体,在平均诊断年龄为65岁或更年轻的家系中观察到更强的连锁证据(LOD = 3.3)。其他显示跨层连锁存在异质性证据的染色体是7号染色体,在无男性对男性疾病传递的家系中连锁信号最强(7q21.11,LOD = 4.1),以及21号染色体,在有非裔美国人血统的家系中连锁信号最强(21q22.13 - 22.3;LOD = 3.2)。我们的研究结果表明了几个可能包含某些基因的区域,这些基因发生突变时会使男性易患更具侵袭性的前列腺癌表型。这为识别这些基因的尝试提供了基础,对侵袭性前列腺癌男性及其亲属具有潜在的临床应用价值。